NICE guidance on trastuzumab for the treatment of HER2-positive metastatic gastric cancer.
Joanne
J
Holden
Zoe
Z
Garrett
Andrew
A
Stevens
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017048:Health Care Costs; D006801:Humans; D017410:Practice Guidelines as Topic; D019057:Quality-Adjusted Life Years; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis / Q000037:antagonists & inhibitors*; D013274:Stomach Neoplasms / Q000737:chemistry / Q000188:drug therapy*; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human